{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-037151","form_type":"8-K","ticker":"IRON","cik":"0001816736","company_name":"Disc Medicine, Inc.","filed_at":"2023-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.731037+00:00","generated_at":"2026-06-19T14:21:40.857079+00:00","sec_items":["1.01","7.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Disc Medicine raises $62.5M in registered direct offering led by Bain Capital Life Sciences","bullets":["Gross proceeds $62.5M from offering of 1,488,166 shares at $23.00 and pre-funded warrants for 1,229,224 shares.","Bain Capital Life Sciences contributed $50M; existing investors Access Biotechnology and OrbiMed also participated.","Net proceeds to fund clinical development of bitopertin, DISC-0974, MWTX-003 and for working capital.","Offering expected to close on or about February 15, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-037151","json":"https://secwatch.observer/filing/0001193125-23-037151.json","markdown":"https://secwatch.observer/filing/0001193125-23-037151.md","text":"https://secwatch.observer/filing/0001193125-23-037151.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523037151/0001193125-23-037151-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523037151/d289637d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T14:21:40.857079+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"81efbbcb5d3f0a4c32dee994701ffdf9be5f7f47","claim":"Disc Medicine, Inc. entered into Purchase Agreement with the investors identified therein valued at approximately $62.5 million (effective 2023-02-13).","evidence_excerpt":"On February 13, 2023, Disc Medicine, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the investors identified therein.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1816736/000119312523037151/0001193125-23-037151-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the investors identified therein"},{"label":"Value","value":"approximately $62.5 million"},{"label":"Effective","value":"2023-02-13"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}